Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan.
Department of Health Care Administration and Management, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Ann Clin Microbiol Antimicrob. 2020 Feb 17;19(1):7. doi: 10.1186/s12941-020-00348-0.
Infection is a major complication for patients with haematological malignancies. It is important to better understand the use of antimicrobial agents and antibiotic resistance for appropriate treatment and prevention of drug resistance. However, very few multi-centre analyses have focused on the use of antimicrobial agents and antibiotic resistance have been carried out in Japan. This study aimed to describe the characteristics of the use of antimicrobial agents and antibiotic resistance in patients with haematological malignancies.
We conducted a cross-sectional study using administrative claims data and antimicrobial susceptibility data in Japan. We included patients diagnosed with haematological malignancies, who were hospitalized in a haematology ward between 1 April 2015 and 30 September 2017 in 37 hospitals. Descriptive statistics were used to summarize patient characteristics, antimicrobial utilization, bacterial infections, and antibiotic resistance.
In total, 8064 patients were included. Non-Hodgkin lymphoma (50.0%) was the most common malignancy. The broad-spectrum antibiotics displayed a following antimicrobial use density (AUD): cefepime (156.7), carbapenems (104.8), and piperacillin/tazobactam (28.4). In particular, patients with lymphoid leukaemia, myeloid leukaemia, or myelodysplastic syndromes presented a higher AUD than those with Hodgkin lymphoma, non-Hodgkin lymphoma, or multiple myeloma. The most frequent bacterial species in our study cohort was Escherichia coli (9.4%), and this trend was also observed in blood specimens. Fluoroquinolone-resistant E. coli (3.6%) was the most frequently observed antibiotic-resistant strain, while other antibiotic-resistant strains were rare.
Broad-spectrum antibiotics were common in patients with haematological malignancies in Japan; however, antibiotic-resistant bacteria including carbapenem-resistant or multidrug-resistant bacteria were infrequent. Our results provide nationwide, cross-sectional insight into the use of antimicrobial agents, prevalence of bacteria, and antibiotic resistance, demonstrating differences in antimicrobial utilization among different haematological diseases.
感染是血液恶性肿瘤患者的主要并发症。为了进行适当的治疗和预防耐药性,了解抗菌药物的使用和抗生素耐药性非常重要。然而,在日本,很少有针对抗菌药物使用和抗生素耐药性的多中心分析。本研究旨在描述血液恶性肿瘤患者抗菌药物使用和抗生素耐药性的特点。
我们使用日本的行政索赔数据和抗菌药物敏感性数据进行了一项横断面研究。我们纳入了 2015 年 4 月 1 日至 2017 年 9 月 30 日期间在 37 家医院血液科住院的血液恶性肿瘤患者。采用描述性统计方法总结患者特征、抗菌药物使用、细菌感染和抗生素耐药情况。
共纳入 8064 例患者。非霍奇金淋巴瘤(50.0%)是最常见的恶性肿瘤。广谱抗生素的使用密度(AUD)如下:头孢吡肟(156.7)、碳青霉烯类(104.8)和哌拉西林/他唑巴坦(28.4)。特别是患有淋巴细胞白血病、髓系白血病或骨髓增生异常综合征的患者比患有霍奇金淋巴瘤、非霍奇金淋巴瘤或多发性骨髓瘤的患者 AUD 更高。本研究队列中最常见的细菌种类是大肠埃希菌(9.4%),在血液标本中也观察到了同样的趋势。氟喹诺酮类耐药大肠埃希菌(3.6%)是最常见的耐药菌株,而其他耐药菌株则较为罕见。
日本血液恶性肿瘤患者中广泛使用广谱抗生素;然而,包括碳青霉烯类耐药或多药耐药菌在内的抗生素耐药菌并不常见。我们的研究结果提供了全国范围内横断面抗菌药物使用、细菌流行情况和抗生素耐药性的信息,显示了不同血液疾病之间抗菌药物使用的差异。